Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Array BioPharma Announces Positive Interim Results for Phase 1 Study of Its HER2 Inhibitor, ARRY-380, in Cancer Patients
Array BioPharma Announces Positive Interim Results for Phase 1 Study of Its HER2 Inhibitor, ARRY-380, in Cancer Patients
Array BioPharma Announces Positive Interim Results for Phase 1 Study of Its HER2 Inhibitor, ARRY-380, in Cancer Patients
Submitted by
admin
on December 13, 2009 - 12:08pm
Source:
Earth Times
News Tags:
Array Biopharma
breast cancer
ovarian cancer
gastric cancer
Headline:
Array BioPharma Announces Positive Interim Results for Phase 1 Study of Its HER2 Inhibitor, ARRY-380, in Cancer Patients
Do Not Allow Advertisers to Use My Personal information
